The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gefitinib Tablets Market Research Report 2024
Synopsis
Global Gefitinib Tablets market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gefitinib Tablets market research.
Key manufacturers engaged in the Gefitinib Tablets industry include Qilu Pharmaceutical, Sichuan Kelun Pharmaceutical Co.,Ltd., Jiangsu Hengrui Pharmaceuticals Co.,ltd., Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical (Group) Co., Ltd., Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Shanghai DESANO Pharmaceuticals Holding Co., Ltd., NatcoPharma and AstraZeneca plc, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Gefitinib Tablets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Gefitinib Tablets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gefitinib Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Qilu Pharmaceutical
Sichuan Kelun Pharmaceutical Co.,Ltd.
Jiangsu Hengrui Pharmaceuticals Co.,ltd.
Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd.
Yangtze River Pharmaceutical (Group) Co., Ltd.
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Shanghai DESANO Pharmaceuticals Holding Co., Ltd.
NatcoPharma
AstraZeneca plc
Intelicure Lifesciences
Weefsel Pharma
Taj Pharmaceuticals
Saintroy Lifescience
Actiza Pharmaceutical
Teva
Segment by Type
Original Drugs
Generic Drugs
Segment by Application
Breast Cancer
Lung Cancer
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Gefitinib Tablets report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Global Gefitinib Tablets market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gefitinib Tablets market research.
Key manufacturers engaged in the Gefitinib Tablets industry include Qilu Pharmaceutical, Sichuan Kelun Pharmaceutical Co.,Ltd., Jiangsu Hengrui Pharmaceuticals Co.,ltd., Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical (Group) Co., Ltd., Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Shanghai DESANO Pharmaceuticals Holding Co., Ltd., NatcoPharma and AstraZeneca plc, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Gefitinib Tablets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Gefitinib Tablets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gefitinib Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Qilu Pharmaceutical
Sichuan Kelun Pharmaceutical Co.,Ltd.
Jiangsu Hengrui Pharmaceuticals Co.,ltd.
Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd.
Yangtze River Pharmaceutical (Group) Co., Ltd.
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Shanghai DESANO Pharmaceuticals Holding Co., Ltd.
NatcoPharma
AstraZeneca plc
Intelicure Lifesciences
Weefsel Pharma
Taj Pharmaceuticals
Saintroy Lifescience
Actiza Pharmaceutical
Teva
Segment by Type
Original Drugs
Generic Drugs
Segment by Application
Breast Cancer
Lung Cancer
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Gefitinib Tablets report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Gefitinib Tablets Market Overview
1.1 Product Overview and Scope of Gefitinib Tablets
1.2 Gefitinib Tablets Segment by Type
1.2.1 Global Gefitinib Tablets Market Value Comparison by Type (2023-2029)
1.2.2 Original Drugs
1.2.3 Generic Drugs
1.3 Gefitinib Tablets Segment by Application
1.3.1 Global Gefitinib Tablets Market Value by Application: (2023-2029)
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Other
1.4 Global Gefitinib Tablets Market Size Estimates and Forecasts
1.4.1 Global Gefitinib Tablets Revenue 2018-2029
1.4.2 Global Gefitinib Tablets Sales 2018-2029
1.4.3 Global Gefitinib Tablets Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Gefitinib Tablets Market Competition by Manufacturers
2.1 Global Gefitinib Tablets Sales Market Share by Manufacturers (2018-2023)
2.2 Global Gefitinib Tablets Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Gefitinib Tablets Average Price by Manufacturers (2018-2023)
2.4 Global Gefitinib Tablets Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Gefitinib Tablets, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Gefitinib Tablets, Product Type & Application
2.7 Gefitinib Tablets Market Competitive Situation and Trends
2.7.1 Gefitinib Tablets Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Gefitinib Tablets Players Market Share by Revenue
2.7.3 Global Gefitinib Tablets Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Gefitinib Tablets Retrospective Market Scenario by Region
3.1 Global Gefitinib Tablets Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Gefitinib Tablets Global Gefitinib Tablets Sales by Region: 2018-2029
3.2.1 Global Gefitinib Tablets Sales by Region: 2018-2023
3.2.2 Global Gefitinib Tablets Sales by Region: 2024-2029
3.3 Global Gefitinib Tablets Global Gefitinib Tablets Revenue by Region: 2018-2029
3.3.1 Global Gefitinib Tablets Revenue by Region: 2018-2023
3.3.2 Global Gefitinib Tablets Revenue by Region: 2024-2029
3.4 North America Gefitinib Tablets Market Facts & Figures by Country
3.4.1 North America Gefitinib Tablets Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Gefitinib Tablets Sales by Country (2018-2029)
3.4.3 North America Gefitinib Tablets Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Gefitinib Tablets Market Facts & Figures by Country
3.5.1 Europe Gefitinib Tablets Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Gefitinib Tablets Sales by Country (2018-2029)
3.5.3 Europe Gefitinib Tablets Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gefitinib Tablets Market Facts & Figures by Country
3.6.1 Asia Pacific Gefitinib Tablets Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Gefitinib Tablets Sales by Country (2018-2029)
3.6.3 Asia Pacific Gefitinib Tablets Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Gefitinib Tablets Market Facts & Figures by Country
3.7.1 Latin America Gefitinib Tablets Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Gefitinib Tablets Sales by Country (2018-2029)
3.7.3 Latin America Gefitinib Tablets Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Gefitinib Tablets Market Facts & Figures by Country
3.8.1 Middle East and Africa Gefitinib Tablets Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Gefitinib Tablets Sales by Country (2018-2029)
3.8.3 Middle East and Africa Gefitinib Tablets Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gefitinib Tablets Sales by Type (2018-2029)
4.1.1 Global Gefitinib Tablets Sales by Type (2018-2023)
4.1.2 Global Gefitinib Tablets Sales by Type (2024-2029)
4.1.3 Global Gefitinib Tablets Sales Market Share by Type (2018-2029)
4.2 Global Gefitinib Tablets Revenue by Type (2018-2029)
4.2.1 Global Gefitinib Tablets Revenue by Type (2018-2023)
4.2.2 Global Gefitinib Tablets Revenue by Type (2024-2029)
4.2.3 Global Gefitinib Tablets Revenue Market Share by Type (2018-2029)
4.3 Global Gefitinib Tablets Price by Type (2018-2029)
5 Segment by Application
5.1 Global Gefitinib Tablets Sales by Application (2018-2029)
5.1.1 Global Gefitinib Tablets Sales by Application (2018-2023)
5.1.2 Global Gefitinib Tablets Sales by Application (2024-2029)
5.1.3 Global Gefitinib Tablets Sales Market Share by Application (2018-2029)
5.2 Global Gefitinib Tablets Revenue by Application (2018-2029)
5.2.1 Global Gefitinib Tablets Revenue by Application (2018-2023)
5.2.2 Global Gefitinib Tablets Revenue by Application (2024-2029)
5.2.3 Global Gefitinib Tablets Revenue Market Share by Application (2018-2029)
5.3 Global Gefitinib Tablets Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Qilu Pharmaceutical
6.1.1 Qilu Pharmaceutical Corporation Information
6.1.2 Qilu Pharmaceutical Description and Business Overview
6.1.3 Qilu Pharmaceutical Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Qilu Pharmaceutical Gefitinib Tablets Product Portfolio
6.1.5 Qilu Pharmaceutical Recent Developments/Updates
6.2 Sichuan Kelun Pharmaceutical Co.,Ltd.
6.2.1 Sichuan Kelun Pharmaceutical Co.,Ltd. Corporation Information
6.2.2 Sichuan Kelun Pharmaceutical Co.,Ltd. Description and Business Overview
6.2.3 Sichuan Kelun Pharmaceutical Co.,Ltd. Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Sichuan Kelun Pharmaceutical Co.,Ltd. Gefitinib Tablets Product Portfolio
6.2.5 Sichuan Kelun Pharmaceutical Co.,Ltd. Recent Developments/Updates
6.3 Jiangsu Hengrui Pharmaceuticals Co.,ltd.
6.3.1 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Corporation Information
6.3.2 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Description and Business Overview
6.3.3 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Gefitinib Tablets Product Portfolio
6.3.5 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Recent Developments/Updates
6.4 Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd.
6.4.1 Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd. Corporation Information
6.4.2 Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd. Description and Business Overview
6.4.3 Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd. Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd. Gefitinib Tablets Product Portfolio
6.4.5 Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd. Recent Developments/Updates
6.5 Yangtze River Pharmaceutical (Group) Co., Ltd.
6.5.1 Yangtze River Pharmaceutical (Group) Co., Ltd. Corporation Information
6.5.2 Yangtze River Pharmaceutical (Group) Co., Ltd. Description and Business Overview
6.5.3 Yangtze River Pharmaceutical (Group) Co., Ltd. Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Yangtze River Pharmaceutical (Group) Co., Ltd. Gefitinib Tablets Product Portfolio
6.5.5 Yangtze River Pharmaceutical (Group) Co., Ltd. Recent Developments/Updates
6.6 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
6.6.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Corporation Information
6.6.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Description and Business Overview
6.6.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Gefitinib Tablets Product Portfolio
6.6.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments/Updates
6.7 Shanghai DESANO Pharmaceuticals Holding Co., Ltd.
6.6.1 Shanghai DESANO Pharmaceuticals Holding Co., Ltd. Corporation Information
6.6.2 Shanghai DESANO Pharmaceuticals Holding Co., Ltd. Description and Business Overview
6.6.3 Shanghai DESANO Pharmaceuticals Holding Co., Ltd. Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Shanghai DESANO Pharmaceuticals Holding Co., Ltd. Gefitinib Tablets Product Portfolio
6.7.5 Shanghai DESANO Pharmaceuticals Holding Co., Ltd. Recent Developments/Updates
6.8 NatcoPharma
6.8.1 NatcoPharma Corporation Information
6.8.2 NatcoPharma Description and Business Overview
6.8.3 NatcoPharma Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.8.4 NatcoPharma Gefitinib Tablets Product Portfolio
6.8.5 NatcoPharma Recent Developments/Updates
6.9 AstraZeneca plc
6.9.1 AstraZeneca plc Corporation Information
6.9.2 AstraZeneca plc Description and Business Overview
6.9.3 AstraZeneca plc Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AstraZeneca plc Gefitinib Tablets Product Portfolio
6.9.5 AstraZeneca plc Recent Developments/Updates
6.10 Intelicure Lifesciences
6.10.1 Intelicure Lifesciences Corporation Information
6.10.2 Intelicure Lifesciences Description and Business Overview
6.10.3 Intelicure Lifesciences Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Intelicure Lifesciences Gefitinib Tablets Product Portfolio
6.10.5 Intelicure Lifesciences Recent Developments/Updates
6.11 Weefsel Pharma
6.11.1 Weefsel Pharma Corporation Information
6.11.2 Weefsel Pharma Gefitinib Tablets Description and Business Overview
6.11.3 Weefsel Pharma Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Weefsel Pharma Gefitinib Tablets Product Portfolio
6.11.5 Weefsel Pharma Recent Developments/Updates
6.12 Taj Pharmaceuticals
6.12.1 Taj Pharmaceuticals Corporation Information
6.12.2 Taj Pharmaceuticals Gefitinib Tablets Description and Business Overview
6.12.3 Taj Pharmaceuticals Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Taj Pharmaceuticals Gefitinib Tablets Product Portfolio
6.12.5 Taj Pharmaceuticals Recent Developments/Updates
6.13 Saintroy Lifescience
6.13.1 Saintroy Lifescience Corporation Information
6.13.2 Saintroy Lifescience Gefitinib Tablets Description and Business Overview
6.13.3 Saintroy Lifescience Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Saintroy Lifescience Gefitinib Tablets Product Portfolio
6.13.5 Saintroy Lifescience Recent Developments/Updates
6.14 Actiza Pharmaceutical
6.14.1 Actiza Pharmaceutical Corporation Information
6.14.2 Actiza Pharmaceutical Gefitinib Tablets Description and Business Overview
6.14.3 Actiza Pharmaceutical Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Actiza Pharmaceutical Gefitinib Tablets Product Portfolio
6.14.5 Actiza Pharmaceutical Recent Developments/Updates
6.15 Teva
6.15.1 Teva Corporation Information
6.15.2 Teva Gefitinib Tablets Description and Business Overview
6.15.3 Teva Gefitinib Tablets Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Teva Gefitinib Tablets Product Portfolio
6.15.5 Teva Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gefitinib Tablets Industry Chain Analysis
7.2 Gefitinib Tablets Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gefitinib Tablets Production Mode & Process
7.4 Gefitinib Tablets Sales and Marketing
7.4.1 Gefitinib Tablets Sales Channels
7.4.2 Gefitinib Tablets Distributors
7.5 Gefitinib Tablets Customers
8 Gefitinib Tablets Market Dynamics
8.1 Gefitinib Tablets Industry Trends
8.2 Gefitinib Tablets Market Drivers
8.3 Gefitinib Tablets Market Challenges
8.4 Gefitinib Tablets Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
